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In the absence of a vaccine, there is an urgent need for the development of safe and effective topical
microbicides to prevent the sexual transmission of human immunodeficiency virus type 1 (HIV-1). In this
study, we proposed to develop a novel class of microbicides using syndecan as the antiviral agent. Specifically,
we generated a soluble syndecan-Fc hybrid molecule by fusing the ectodomain of syndecan-1 to the Fc domain
of a human IgG. We then tested the syndecan-Fc hybrid molecule for various in vitro microbicidal anti-HIV-1
properties. Remarkably, the syndecan-Fc hybrid molecule possesses multiple attractive microbicidal proper-
ties: (i) it blocks HIV-1 infection of primary targets including T cells, macrophages, and dendritic cells (DC);
(ii) it exhibits a broad range of antiviral activity against primary HIV-1 isolates, multidrug resistant HIV-1
isolates, HIV-2, and simian immunodeficiency virus (SIV); (iii) it prevents transmigration of HIV-1 through
human primary genital epithelial cells; (iv) it prevents HIV-1 transfer from dendritic cells to CD4 T cells; (v)
it is potent when added 2 h prior to addition of HIV-1 to target cells; (vi) it is potent at a low pH; (vii) it blocks
HIV-1 infectivity when diluted in genital fluids; and (viii) it prevents herpes simplex virus infection. The
heparan sulfate chains of the syndecan-Fc hybrid molecule are absolutely required for HIV-1 neutralization.
Several lines of evidence suggest that the highly conserved Arg298 in the V3 region of gp120 serves as the locus
for the syndecan-Fc hybrid molecule neutralization. In conclusion, this study suggests that the syndecan-Fc
hybrid molecule represents the prototype of a new generation of microbicidal agents that may have promise for
HIV-1 prevention.
The dominant cell surface heparan sulfate proteoglycans
(HSPG) (25, 29, 30, 33) are syndecans, which are transmem-
brane receptors highly expressed on adherent cells (macro-
phages and epithelial and endothelial cells) but poorly ex-
pressed on suspension cells (T cells) (2, 3, 4, 10, 35). Their
ectodomain bears three linear heparan sulfate (HS) chains,
which are composed of a repetition of a sulfated disaccharide
motif (1). The sulfation pattern of HSs dictates the ligand
specificity of syndecans (1). HSPG, including syndecans, serve
as receptors for human deficiency virus type-1 (HIV-1) (16),
herpes simplex virus (HSV) (7), human papillomavirus (HPV)
(13, 37), and human T-lymphotropic virus type 1 (HTLV-1)
(19, 20). Pretreatment of target cells such as macrophages with
heparinase, an enzyme that removes HS moieties from synde-
cans, significantly reduces HIV-1 infectivity (35). Although
syndecans do not alleviate the requirement for CD4 and che-
mokine receptors for viral entry (35), these in cis attachment
receptors amplify HIV-1 infection by promoting viral adsorp-
tion to the surface of permissive cells. Syndecans also serve as
in trans receptors for HIV-1 (2, 16). HIV-1 binds syndecans
richly expressed on the endothelium and remains infectious for
a week, whereas cell-free virus loses its infectivity after a single
day (2). Moreover, HIV-1 attached onto the endothelium via
syndecans represents an in trans source of infection for circu-
lating T cells (2). Primary HIV-1, HIV-2, and simian immuno-
deficiency virus (SIV) isolates produced from peripheral blood
mononuclear cells (PBMCs) exploit syndecans (2). Further-
more, syndecans on microvascular endothelial cells play a sig-
nificant role in cell-free HIV-1 transmigration through the
blood-brain barrier (3). Thus, HIV-1 has maximized its utili-
zation of syndecans in the body.
A single conserved arginine (Arg298) in the V3 region of
gp120 governs HIV-1 binding to syndecans (11). An amine
group on the side chain of this residue is absolutely required
for syndecan utilization by HIV-1 (11). HIV-1 binds syndecans
via a 6-O sulfation (11) within the HS chains, demonstrating
that this binding is not the result of random interactions be-
tween basic residues and negative charges but the result of
specific contacts between gp120 and a well-defined sulfation in
syndecans. Surprisingly, the Arg298 in gp120 that mediates
HIV-1 binding to syndecans also mediates HIV-1 binding to
CCR5 (42), suggesting that HIV-1 recognizes similar motifs on
syndecans and CCR5 (11). Supporting this hypothesis, the 6-O
sulfation recognized by HIV-1 on syndecans mimics the sul-
fated tyrosines recognized by HIV-1 in the N terminus of
CCR5 (11). The finding that CCR5 and syndecans are ex-
ploited by HIV-1 via a single determinant echoes the mecha-
nisms by which chemokines utilize these two disparate recep-
tors and suggests that the gp120/chemokine mimicry may
represent a common strategy in microbial pathogenesis.
More recent work suggests that syndecans play a critical role
in HIV-1 transmission (4). HIV-1 transmission includes trans-
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migration of HIV-1 through the genital epithelium and subse-
quent capture and transfer of infectious particles from den-
dritic cells (DC) and/or Langerhans cells (LC) to T cells (31,
34, 38). Importantly, human cervical and vaginal mucosal
epithelia richly express syndecans in vivo (4). HS chain removal
by heparinase treatment prevents HIV-1 transcytosis through
primary human cervical and vaginal mucosal epithelia (4). The
Arg298 V3 HIV-1 mutant, which cannot interact with synde-
cans (11), fails to transcytose (4). Thus, syndecans facilitate
HIV-1 epithelial transmigration in vitro. More recently, we
identified syndecan-3 as an HIV-1 receptor on DC (12). Syn-
decan-3 stabilizes the captured virus, enhances DC infection in
cis, and promotes transfer to T cells (12). Removal of the HS
from the cell surface by heparinase or by silencing syndecan-3
by small interfering RNA (siRNA) partially inhibited HIV-1
transmission by immature DC (12), whereas neutralizing both
syndecan-3 and DC-SIGN abrogated HIV-1 capture and sub-
sequent transmission (12). Our findings that syndecans modu-
late both HIV-1 epithelial transmigration and HIV-1 transfer
from DC to CD4 T cells suggest that syndecans represent
new targets for the development of topical microbicides.
Nearly 40 million people currently live with HIV-1/AIDS;
the majority of them reside in developing countries. It has been
estimated that there are over 14,000 new HIV-1 infections per
day in adults aged 15 to 50 years, with 50% of the newly
infected being women aged 15 to 24 years (21, 22). In the
absence of a vaccine, there is thus an urgent need for the
development of safe and effective topical microbicides to pre-
vent the sexual transmission of HIV-1 (14, 26). Topical micro-
bicides are currently defined as vaginally or rectally applied
products that prevent male-to-female or female-to-male trans-
mission of HIV-1 infectious particles (39).
In this study, we proposed to develop a novel class of mi-
crobicides using syndecan as the antiviral agent. Specifically,
we generated a soluble syndecan-Fc hybrid molecule by fusing
the ectodomain of syndecan-1 to the Fc domain of a human
IgG. We then tested this syndecan-Fc hybrid molecule for its in
vitro microbicidal properties. Remarkably, the syndecan-Fc hy-
brid molecule possesses multiple attractive microbicidal prop-
erties: (i) it blocks HIV-1 infection of primary targets including
T cells, macrophages, and DC; (ii) it exhibits a broad range of
antiviral activity against primary HIV-1 isolates, multidrug-
resistant HIV-1 isolates, HIV-1, and SIV; (iii) it prevents trans-
migration of HIV-1 through human primary genital epithelial
cells (PGEC); (iv) it prevents HIV-1 transfer from DC to
CD4 T cells; (v) it is potent when added 2 h prior to addition
of HIV-1 to target cells; (vi) it is potent at a low pH; (vii) it
blocks HIV-1 infectivity when diluted in genital fluids; and
(viii) it inhibits HSV infection. Thus, this syndecan-Fc hybrid
molecule represents the prototype of a new generation of mi-
crobicidal agents that may have promise for HIV-1 prevention.
MATERIALS AND METHODS
Viruses. 293T cells were transfected with proviral plasmid (9 g) and vesicular
stomatitis virus G (VSV-G) envelope plasmid (1 g). At day 2, VSV-G
pseudotyped viruses (5 g of p24) were harvested and used to acutely infect
Jurkat cells (2  106 cells). Two days after infection, viruses were harvested, and
p24 content was measured by enzyme-linked immunosorbent assay (ELISA;
PerkinElmer, Waltham, MA). The following proviral constructs were used: wild-
type pNL4.3 (X4); pNL4.3-BaL (R5), in which the wild-type NL4.3 envelope was
switched for the R5 BaL envelope; pNL4.3Env, which lacks gp160; and pNL4.3-
eGFP (X4) and pNL4.3-BaL-eGFP (R5), which encode the enhanced green
fluorescent protein (eGFP) gene instead of the nef gene (6). Primary HIV-1,
drug-resistant HIV-1, HIV-2, and SIV were obtained through the National
Institutes of Health (NIH) AIDS Research and Reference Reagent Program and
amplified in activated human PBMCs (5  106 cells) as described previously (5).
The following HIV-1 group M viruses were used: (i) 92RW021, a subtype A Env,
subtype A, R5 virus (contributed by WHO Network for HIV Isolation and
Characterization); (ii) 92UG029, a subtype A Gag, subtype A Env, X4 (syncytium-
inducing [SI]) virus (WHO Network for HIV Isolation and Characterization);
(iii) 92TH026, a subtype B Gag, subtype B Env, R5 (non-syncytium-inducing
[NSI]) virus (the UNAIDS Network for HIV Isolation and Characterization);
(iv) 92HT599, a subtype B Env, X4 (SI) virus (Neal Halsey and the Division of
AIDS [DAIDS], NIAID); (v) 93IN101, a subtype C Env, R5 (NSI) virus (Robert
Bollinger and the UNAIDS Network for HIV Isolation and Characterization and
the DAIDS, NIAID); (vi) 98IN017, a subtype C Env, X4 virus (Robert Bollinger
and the UNAIDS Network for HIV Isolation and Characterization and the
DAIDS, NIAID; courtesy of the NIBSC Center for AIDS Reagents, United
Kingdom); (vii) 92UG005, a subtype D Gag, subtype D Env, R5 virus (UNAIDS
Network for HIV Isolation and Characterization and the DAIDS, NIAID); (viii)
92UG024, a subtype D Gag, subtype D Env, X4 (SI) virus (UNAIDS Network
for HIV Isolation and Characterization and the DAIDS, NIAID); (ix) 92TH006,
a subtype E Env, R5 (NSI) virus (UNAIDS Network for HIV Isolation and
Characterization and the DAIDS, NIAID); (x) 93TH053, a subtype E Env, X4
virus (UNAIDS Network for HIV Isolation and Characterization and the
DAIDS, NIAID); (xi) 93BR029, a subtype F Gag, subtype F Env, R5 (NSI) virus
(UNAIDS Network for HIV Isolation and Characterization and the DAIDS,
NIAID); (xii) 93BR020, a subtype F Gag, subtype F Env subtype, R5 and X4 (SI)
virus (UNAIDS Network for HIV Isolation and Characterization and the
DAIDS, NIAID); (xiii) RU132, a subtype G Env, R5 virus (A. Bobkov, D. I.
Ivanovsky Institute of Virology, Moscow, Russia; supplied by Jonathon Weber,
Imperial College, London, United Kingdom); (xiv) Jv1083, a subtype G Env, R5
virus (A. Abimiku); and (xv) JR-CSF, a laboratory-adapted R5 (NSI) virus (I.
Chen). The following drug-resistant viruses were used: HIV-174V/MT-2, a re-
verse transcriptase (RT) inhibitor-resistant X4 virus (HXB2; contributed by B.
Larder, courtesy of the MRC AIDS Directed Program) (abbreviated RT74V);
HIV-1LAI-M184V (lamivudine [3TC]-resistant), an RT inhibitor-resistant X4 virus
(LAI; J. Mellors and R. Schinazi) (RTM184V); HIV-1 M46I/L63P/V82T/I84V, a
protease (PR) inhibitor-resistant R5X4 virus (E. Emini) (PRM46I/L63P/V82T/I84V);
and pNL4-3 gp41 (36G) V38A/N42D, a fusion inhibitor (T20)-resistant X4 virus
(Trimeris, Inc.) (T20V38A/N42D). The following additional retroviruses were used:
SIVmac251/43H (contributed by R. Desrosiers), SIVsyk1.2 (V. Hirsch and P.
Johnson), HIV-2CDC310342 (M. Rayfield for S. Wiktor), and HIV-27312A (F. Gao
and B. Hahn).
Cells. TZM-bl cells were obtained through the NIH AIDS Research and
Reference Reagent Program. TZM-bl cells express CD4, CXCR, and CCR5,
which render them susceptible to infection, and contain an integrated Escherichia
coli lacZ gene driven by the HIV-1 long terminal repeat (LTR) (44). Upon
infection, Tat production from the integrated provirus leads to activation of the
lacZ reporter, resulting in synthesis of -galactosidase in these cells. Infected
cells are identified by enzymatic activity measurement at 48 h postinfection,
allowing quantitation after a single round of infection, as described previously
(44). Blood-derived CD4 T lymphocytes, macrophages, and DC were isolated
as described previously (5). Briefly, human PBMCs were purified from fresh
blood by banding on Ficoll-Hypaque (30 min at 800 g at 25°C) (GE Healthcare
Bio-Sciences Corp., Piscataway, NJ). Primary human CD4 T cells were purified
from PBMCs by positive selection with anti-CD4 Dynabeads and subsequent
release using Detachabead (Invitrogen Corp., Carlsbad, CA). Cells were cul-
tured in RPMI medium 1640 (Invitrogen Corp., Carlsbad, CA) supplemented
with 10% fetal calf serum (FCS; Thermo Fisher Scientific Inc., Waltham, MA),
minimal essential medium (MEM) amino acids, L-glutamine, MEM vitamins,
sodium pyruvate (Invitrogen Corp., Carlsbad, CA), and penicillin plus strepto-
mycin (Mediatech, Inc., Manassas, VA) and were subsequently activated with
bacterial superantigen staphylococcal enterotoxin B (SEB; 100 ng/ml) and mito-
mycin C-killed PBMCs from another donor (cell ratio of 10:1 PBMCs to CD4
cells). Three days after stimulation, cells were split 1:2 in medium containing
interleukin-2 ([IL-2] final concentration, 200 units/ml; NIH AIDS Research and
Reference Reagent Program). Cultures were then split 1:2 every 2 days in IL-2
medium and infected with HIV-1 at 7 days after stimulation. For generating
primary human macrophages, monocytes were purified from human PBMCs by
negative selection (Invitrogen Corp., Carlsbad, CA) and activated and cultured
at a cell concentration of 106 cells/ml in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% FCS (Thermo Fisher Scientific Inc., Waltham,
MA), MEM amino acids, L-glutamine, MEM vitamins, sodium pyruvate (Invitro-
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gen Corp., Carlsbad, CA), penicillin (100 units/ml), streptomycin (100 mg/ml),
and 50 ng/ml recombinant human granulocyte-macrophage colony-stimulating
factor (GM-CSF) (R&D Systems Inc., Minneapolis, MN) and maintained at
37°C in a humidified atmosphere supplemented with 5% CO2. To obtain mono-
cyte-derived macrophages, cells were allowed to adhere to plastic and cultured
for 6 days to allow differentiation. Immature DC were cultured from monocytes
in the presence of IL-4 and GM-CSF (500 and 800 units/ml, respectively). At day
7, the phenotype of the cultured DC was confirmed by flow cytometric analysis.
PGEC were provided by B. Kahn of the Department of Obstetrics and Gyne-
cology at Scripps Clinic, La Jolla, CA. By rotation of cotton swabs against the
vaginal walls, several million cells were collected per individual. Cells were
immediately placed in sterile phosphate-buffered saline (PBS), held at 4°C, and
transported to the laboratory. After centrifugation (at 300 g for 5 min), the cell
pellet was digested in 1 mg/ml collagenase/dispase (Roche Diagnostics Corp.,
Roche Applied Science, Indianapolis, IN) containing 1 mg/ml DNase (Sigma-
Aldrich, St. Louis, MO) and 0.15 mg/ml Na-p-tosyl-L-lysine chloromethyl ketone
(Sigma-Aldrich, St. Louis, MO) for 1 h at 37°C. The digest was spun down
(1,000 g for 20 min) and resuspended in 250 mg/ml PBS-bovine serum albumin
(BSA). After additional centrifugation, the pellet was resuspended in 5 mg/ml
PBS-BSA and loaded onto a 50% Percoll gradient. PGEC were then isolated
from contaminating cells by fluorescence-activated cell sorting (FACS) as de-
scribed previously (4) and propagated into collagen type I-coated T-25 flasks in
DMEM-F12 medium containing 10% FCS and epithelial cell growth supplement
(100 g/ml) (Sigma-Aldrich, St. Louis, MO). PGEC were purified using mag-
netic cell sorting (MACS) columns (Miltenyi Biotec Inc., Auburn, CA) and
MACS beads (Miltenyi Biotec Inc., Auburn, CA) coated with antibodies directed
against specific cytokeratin (CK) members. Specifically, the following antibodies
were used: CK3-3E4 (Miltenyi Biotec Inc., Auburn, CA), which recognizes CK8,
CK18, and CK19; the CK3-6H5 (Miltenyi Biotec Inc., Auburn, CA), which
recognizes CK7 and CK8; LL025 (Novocastra Laboratories, Ltd., Newcastle,
United Kingdom), which recognizes CK16; and SY5 (Novocastra Laboratories
Ltd., Newcastle, United Kingdom), which recognizes involucrin. As a second
source of PGEC, cells were obtained from BioWhittaker (customized request)
(BioWhittaker, Inc., Walkersville, MD). PGEC were passaged fewer than three
times before use to maintain their original features.
Genital fluids and seminal plasma. To collect genital and vaginal fluid/mucus,
swabs were kept in the cervix and in the posterior vaginal fornix for about 20 s.
Each swab was placed in a test tube containing 0.5 ml of PBS. A swab absorbs
approximately 150 l of fluid when saturated, and the average dilution of vaginal/
cervical sample in the buffer will be approximately 1:5. The specimens were
centrifuged at 15,000 rpm at 4°C for 10 min, and supernatants were pooled and
stored at 80°C until use. Specimens were obtained from Lee Biosolutions Inc.,
St. Louis, MO. To collect seminal plasma, ejaculates were centrifuged at 1,300  g
for 15 min at 4°C to separate spermatozoa from seminal plasma. The seminal
plasma was further clarified by centrifugation at 10,000  g for 15 min, and
supernatant was collected and stored at 80°C for further use. Specimens were
obtained from GeneWay, San Diego, CA.
Infections. TZM-bl cells (44) (100,000 cells/ml) were exposed to HIV-1 (100
pg of p24) for 4 h together with or without Fc proteins and washed, and infection
was measured 48 h after infection by -galactosidase activity. For 50% and 90%
inhibitory concentration (IC50 and IC90, respectively) measurements, TZM-bl
cells were exposed to HIV-1 variants (primary isolates and drug-resistant viruses)
or HIV-2 and SIV isolates at 37°C in the presence of increasing concentrations
of syndecan-1-Fc or control Fc. Viruses and Fc proteins were washed away after
4 h. Infection was measured 48 h after infection by -galactosidase activity.
Results (triplicate) were expressed in concentration (g/ml) of Fc proteins re-
quired to inhibit 50% or 90% of virus infectivity. IC50 and IC90 measurements
presented were representative of three independent experiments. To examine
the inhibitory effect of Fc proteins on HIV-1 infection of primary cells, DC,
CD4 T lymphocytes, or macrophages (0.1  106 cells) were exposed to virus
(1 ng of p24) for 1 day in the presence or absence of Fc proteins, washed three
times with medium, and cultured in a flat-bottom 96-well plate. Supernatants
were collected after different days, and viral replication was monitored by p24
ELISA (PerkinElmer, Waltham, MA). For cell-to-cell infection, activated PB-
MCs (200,000 cells) were infected with JR-CSF (500 pg of p24) for 3 days,
washed three times to remove cell-free virus, and added to TZM-bl cells in the
presence of increasing concentrations of syndecan-1-Fc or control Fc (0.1 to 100
g/ml) diluted in a pool (n  6) of seminal plasma. Infection was scored as
above.
Transmigration assay. The HIV-1 transmigration assay using PGEC seeded
onto polycarbonate membrane transwells was conducted as described previously
(4). Briefly, PGEC were seeded onto the upper face of collagen I and fibronec-
tin-coated 12-mm-diameter, 3-m-pore-size polycarbonate membrane transwells
at a density of 105 cells per well and were cultured until formation of tight
junctions was achieved. The inserts were fed every 2 days. The monolayer on the
filter effectively divides the well into an apical compartment and a basolateral
compartment. The integrity of each cell monolayer was measured using an
epithelial volt-ohm meter (Millipore Inc., Billerica, MA). To ensure the integrity
of the PGEC barrier, we monitored the elevated transepithelial electrical resis-
tance of each cell monolayer and measured the paracellular passage of the
extracellular marker inulin by determination of the permeability coefficient as
evaluated by a diffusion assay using [14C]carboxylated inulin (Sigma-Aldrich, St.
Louis, MO) (molecular weight, 5,000) in the upper chamber, as we described
previously (4). After verifying the integrity of the monolayer on the transwell
filters, PGEC were exposed to HIV-1 (added to the upper chamber), and viral
transcytosis was monitored by measuring amounts of particulate capsid in the
basal chamber by p24 ELISA. We eliminated free capsid from particulate capsid
by microcentrifuging medium collected from the basal chamber for 90 min at
4°C. The integrity of the monolayer of PGEC was preserved even 8 h after virus
exposure (4). We verified by ELISA (horseradish peroxidase anti-human Fc
antibody detection) that the Fc proteins did not cross the PGEC monolayer,
indicating that the Fc fusion protein cannot act on transcytosed viruses. After
particulate capsid measurement by p24 ELISA, infectivity of transcytosed viruses
(1 ng of p24) was confirmed using TZM-bl indicator cells.
DC transmission assay. Blood-derived immature DC were plated at 50,000
cells per well in 96-well v-bottom plates (BD Biosciences, San Jose, CA). Cells
were incubated with NL4.3-eGFP (X4), NL4.3-BaL-eGFP (R5), or the single-
round NL4.3Env-eGFP pseudotyped with NL4.3 gp160 (X4) (25 ng of p24) for
2 h at 37°C. Cells were washed three times with warm medium, and CCR5
Jurkat T cells (100,000 cells) were added. Cells were cultured in a flat-bottom
96-well plate, harvested after 3 days, and fixed in 4% paraformaldehyde-PBS,
and GFP expression was measured by FACS. The percentage of infected Jurkat
T cells was selectively quantified by gating T cells using an anti-CD3 antibody as
described previously (5).
Syndecan-1-Fc plasmid construction. The ectodomain of human syndecan-1
was subcloned by PCR amplification. The amplified DNA product was digested
with NotI and BamHI, gel purified, and ligated in frame with the Fc domain of
human IgG1 in pCR3 as described previously (10). For amplification of the
expression of Fc and syndecan-1-Fc protein, the glutamate synthetase (GS)
amplification system was used as described previously (10). This system uses a
vector that has the gene of interest and a GS gene, which allows selection and
amplification in a glutamine-free environment in the presence of methionine
sulfoximine, an inhibitor of the GS encoded by the vector and the CHO cells. For
this purpose the Fc and syndecan-1-Fc fragments were subcloned under the
control of the cytomegalovirus promoter in pRSC, a mammalian expression
vector with two transcriptional units, as described previously (10). The GS gene
was cloned by PCR amplification from a CHO cDNA library. The sense (5-C
CCACACCAAGCTTCTCGCCGCTC-3) and antisense (5-GATGAACTAGG
AAAGCTTCAAGATCACTCAAAG-3) primers, including HindIII sites (un-
derlined), were designed from the nucleotide sequence of the GS gene as
described previously (10). The PCR product was digested with HindIII and
cloned under the control of the Rous sarcoma virus promoter in pRSC. The
3HS-syndecan-1-Fc devoid of its three HS chains was created by site-directed
mutagenesis by replacing serines 37, 45, and 47 with alanines.
Expression, amplification, and purification of the syndecan-1-Fc fusion pro-
tein. For production of stable cell lines expressing Fc and syndecan-1-Fc, 106
CHO-K1 cells were transfected with 10 g of pRSC-GS-Fc, pRSC-GS-syndecan-
1-Fc, and pRSC-GS-3HS syndecan-1-Fc. At 36 h posttransfection, cells were
trypsinized, plated in 96-wells of a microtiter plate, and grown in glutamine-free
DMEM containing 25 M methionine sulfoximine. After 14 to 21 days, clones
surviving the selection were transferred to T25 flasks and grown to confluence.
Supernatants were then harvested and incubated with 15 l of protein A-Tri-
sacryl at 4°C for 12 h. After three washes in PBS, beads were eluted in 25 l of
sodium dodecyl sulfate (SDS) sample buffer and loaded on an SDS–4 to 16%
polyacrylamide gel, and the presence of Fc and syndecan-1-Fc proteins was
analyzed by Western blotting with antibodies directed against human IgG1 Fc
(GE Healthcare Bio-Sciences Corp., Piscataway, NJ). Blots were revealed by an
enhanced chemiluminescence procedure (Thermo Fisher Scientific, Rockford,
IL). Recombinant Fc and syndecan-1-Fc proteins were batch purified by affinity
chromatography over protein A as specified by the manufacturer (Thermo Fisher
Scientific, Rockford, IL). The concentrations of purified Fc and syndecan-1-Fc
recombinant proteins were determined using a bicinchoninic acid protein assay
(Thermo Fisher Scientific, Rockford, IL). Syndecan-1-Fc was incubated with
heparinase I, II, and III (0.3 mIU) (Sigma-Aldrich, St. Louis, MO) for 2 h at 37°C
to remove HS chains from the core protein.
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Syndecan-1-Fc ELISA. Nunc MaxiSorb eight-well strip plates were coated with
anti-syndecan-1 IgG (clone ID4) or control isotype IgG (10 g/ml) for 16 h at
4°C. Wells were washed extensively and blocked in PBS-BSA (1 mg/ml) for 4 h
at room temperature. Medium containing (or not) syndecan-1-Fc was added to
wells overnight at 4°C. Wells were washed, and captured syndecan-1-Fc mole-
cules were revealed using anti-human Fc-horseradish peroxidase-IgG (1 g/ml).
Wells were washed, and o-phenylenediamine dihydrochloride substrate was
added. After color development, the reaction was stopped with 4N sulfuric acid,
and wells (triplicate) were read on a plate reader at 490 nm.
Cytotoxicity. Cells were plated in clear-bottom 96-well plates (BD Biosciences,
San Jose, CA). Cells were serially diluted from 55,000 cells to 25 cells in 100 l
of complete DMEM or RPMI medium. Fifteen microliters of the CellQuanti-
MTTTM reagent (Gentaur, Kampenhout, Belgium) was added, and cells were
incubated for 4 h at 37°C. Then, 100 l of the solubilization solution was added,
and the plate was shaken for 1 h at room temperature. The A570 was measured
on a SpectraMax 384 Plus reader (Molecular Devices, Sunnyvale, CA). A linear
relationship was observed between the A570 value and the cell number. The
detection limit was estimated to be 950 cells from the blank control. To deter-
mine the cytotoxicity of Fc proteins on cells, 55,000 cells were plated per 80-l
well in clear-bottom 96-well plates. Cells were treated twice daily with 200 g/ml
of syndecan-1-Fc, Fc, or 0.01% saponin (Sigma-Aldrich, St. Louis, MO) for a
week. No washes were performed to maintain a continuous exposure of cells to
Fc proteins.
RESULTS
Construction, expression, amplification, and purification of
the syndecan-Fc hybrid molecule. The ectodomain of human
syndecan-1 was subcloned in frame with the Fc domain of
human IgG1. For amplification of the expression of Fc and
syndecan-1-Fc, a GS amplification system was used that allows
selection and amplification in CHO cells in a glutamine-free
environment in the presence of methionine sulfoximine, an
inhibitor of the GS encoded by the vector (10). For production
of stable cell lines expressing Fc and syndecan-1-Fc, CHO cells
were transfected with pRSC-GS-Fc and pRSC-GS-syndecan-
1-Fc and grown in G-DMEM containing methionine sulfoxi-
mine. After 2 to 3 weeks of selection, clone supernatants were
analyzed for Fc content by Western blotting using anti-Fc
antibodies (Fig. 1; Fc and wild-type syndecan-1-Fc, lanes 1 and
2, respectively). Positive clones were then amplified for 2 to 3
additional weeks, and Fc and syndecan-1-Fc proteins were
batch purified from 1 to 2 liters of cell supernatant by protein
A affinity. The rationale for linking syndecan-1 to the Fc of
human IgG1 was that the Fc moiety allowed efficient secretion
of a syndecan molecule, which harbored heparan sulfate
chains, into the extracellular medium and allowed subsequent
affinity purification on a protein A column. Moreover, the Fc
moiety was extremely useful to conduct ELISA, FACS analy-
sis, and pulldown studies. Syndecan-1 was chosen because it is
the most studied syndecan member and because it is highly
expressed on genital epithelial cells (4).
Anti-HIV-1 spectrum of the syndecan-Fc hybrid molecule.
We first tested the ability of the syndecan-Fc hybrid molecule
to block the infection of CD4 CXCR4 CCR5 HeLa
TZM-bl reporter (-galactosidase) cells by three distinct cat-
egories of viruses. The first category includes HIV-1 isolates
representative of various HIV-1 subtypes with different core-
ceptor usage, either CCR5 (R5 viruses) or CXCR4 (X4 vi-
ruses). The second category includes HIV-1 isolates that are
resistant to reverse transcriptase (RT), protease (PR), or fu-
sion (T20) inhibitors. The third category is other retroviruses
such as HIV-2 and SIV isolates. Viruses were added to
TZM-bl cells together with Fc or syndecan-1-Fc for 4 h; cells
were washed, and infection was measured 48 h after infection
as -galactosidase activity. Importantly, we found that synde-
can-1-Fc, but not Fc, efficiently blocks infection of all HIV-1,
HIV-2, and SIV isolates (Table 1).
The syndecan-Fc hybrid molecule blocks HIV-1 infection of
CD4 T lymphocytes, macrophages, and DC. An ideal micro-
bicide should inhibit HIV-1 infection of primary in vivo targets
of HIV-1. We thus asked whether syndecan-1-Fc could block
HIV-1 infection in human primary CD4 T lymphocytes, mac-
rophages, and DC. Cells were exposed to HIV-1 (R5 JR-CSF)
together with syndecan-1-Fc or Fc control. Twenty-four hours
postinfection, cells were washed, and viral replication was
monitored by measuring the amount of HIV-1 capsid protein
present in the cell culture supernatant by p24 ELISA every 2
days for up to 10 to 14 days thereafter. Remarkably, syndecan-
1-Fc, but not Fc, blocked HIV-1 infection of all three in vivo
cell targets of HIV-1 (Fig. 2A). We conducted similar inhibi-
tory experiments using increasing concentrations of Fc or syn-
decan-1-Fc rather than a fixed concentration of Fc proteins.
IC50 and IC90 values are presented in Table 2. Importantly,
syndecan-1-Fc exhibited no cytotoxic effect on target cells (Fig.
2B). We used the natural detergent saponin as positive control
for cytotoxicity (Fig. 2B). These results suggest that the synde-
can-Fc hybrid molecule has the potential to specifically prevent
infection of T cells, macrophages, and DC during the early
steps of HIV-1 transmission.
Antiviral mechanism of action of the syndecan-Fc hybrid
molecule. After demonstrating the broad potency of the syn-
decan-Fc hybrid molecule at blocking HIV-1 infection of its
primary in vivo targets, we examined its mechanisms of antivi-
ral action. Since we along with others previously reported that
cell surface HSPG including syndecans facilitate the initial
adsorption of the virus onto target cells (16, 25, 29, 30, 33), we
asked whether syndecan-1-Fc interferes with HIV-1 adsorption
onto CD4 T lymphocytes and macrophages. To address this
issue, HIV-1 (JR-CSF) together with Fc or syndecan-1-Fc was
added to CD4 T lymphocytes and macrophages. After 2 h at
4°C, cells were washed and lysed, and amounts of attached
FIG. 1. Western blot analysis of recombinant syndecan-Fc hybrid
molecules. Protein A-purified Fc (1 g) (lane 1), syndecan-1-Fc (1 g)
(lane 2), syndecan-1-Fc (1 g) pretreated for 2 h at 37°C with a mixture
of heparinases I, II and III (10 U) (lane 3), and the heparan sulfate
chainless syndecan-1-Fc mutant called 3HS-syndecan-1-Fc (lane 4)
(1 g) were analyzed by Western blotting using anti-human Fc IgG
(1/1,000 dilution). Fc and syndecan-1-Fc proteins (bands) are
boxed.
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virus were quantified by p24 ELISA. Importantly, the synde-
can-Fc hybrid molecule, but not Fc, profoundly reduced HIV-1
adsorption onto target cells (Fig. 3A). After demonstrating
that syndecan-1-Fc blocks HIV-1 adsorption, we asked
whether it also interferes with the subsequent entry step: the
CD4/coreceptor-mediated internalization. To address this is-
sue, plates containing cells and viruses were first centrifuged at
2,000  g (spinoculation) for 3 h at 4°C to avoid any internal-
ization. The spinoculation step artificially forces the initial
attachment of the virus onto the cells (28). Cells were washed
twice to remove unbound virus and then placed at 37°C for 4 h
to permit internalization in the presence of Fc or syndecan-1-
Fc. Cells were then trypsinized and lysed. Amounts of inter-
nalized virus were quantified by measuring amounts of capsid
in cell lysates by p24 ELISA. We found that syndecan-1-Fc, but
not Fc, significantly prevented HIV-1 internalization into
CD4 T lymphocytes and macrophages (Fig. 3B). Together
these data suggest that the syndecan-Fc hybrid molecule blocks
HIV-1 infection by interfering with HIV-1 entry.
Since we previously obtained evidence that HIV-1–syndecan
interactions are mediated via contacts between the Arg298 of
gp120 and the 6-O sulfation of HS chains of syndecans (11), we
asked whether syndecan-1-Fc mediates its inhibitory effect via
its HS chains. To test this hypothesis, syndecan-1-Fc was pre-
treated with heparinase, which removes HS chains from the
core syndecan protein (1) (Fig. 1, lane 3), and added to CD4
T-lymphocytes together with HIV-1 (JR-CSF). Viral replica-
tion was monitored over a period of 10 days by measuring
amounts of capsid in cell culture supernatant by p24 ELISA. In
contrast to untreated syndecan-1-Fc, heparinase-treated syn-
decan-1-Fc, like Fc, did not influence viral replication in CD4
T lymphocytes (Fig. 4A). This finding suggests that the synde-
can-Fc hybrid molecule mediates its inhibitory effect via its
sulfated heparan chains.
A distinct structural feature of the four syndecans (synde-
can-1 to -4) is a conserved region of three glycosaminoglycan
attachment sites near the N terminus of their core proteins (1,
23, 45). These sites predominantly initiate HS chains (1, 23,
45). To determine whether HS chains are important for the
inhibitory effect of syndecan-1-Fc, we generated 3HS-synde-
can-1-Fc, which is devoid of its three HS chains as a result of
oligonucleotide-directed mutagenesis. Specifically, serine resi-
dues at position 37, 45, and 47 were changed to alanines,
thereby preventing the addition of HS chains at those sites
(Fig. 1, lane 4). Importantly, we found that in contrast to
wild-type syndecan-1-Fc, 3HS-syndecan-1-Fc, like Fc, fails to
block HIV-1 infection of CD4 T lymphocytes (Fig. 4B). This
further demonstrates that the HS chains of the syndecan-Fc
hybrid molecule are responsible for the neutralization of
HIV-1, likely by targeting the highly conserved Arg298 within
gp120 (11).
Antiviral effect of the syndecan-Fc hybrid molecule before,
during, and after virus exposure. To determine the likely du-
ration of antiviral activity of the syndecan-Fc hybrid molecule,
TABLE 1. Syndecan-1-Fc exhibits a broad anti-HIV spectrum
Virus and/or isolate Clade Coreceptorusage
Syndecan-1-Fc activity (g/ml) Fc control activity(g/ml)
IC50 IC90 IC50 IC90
HIV-1 group M isolatesa
92RW021 A R5 1.9 	 0.06 6.1 	 0.2 
100 
100
92UG029 A X4 2.2 	 0.08 8.2 	 0.07 
100 
100
92TH026 B R5 0.3 	 0.02 4.9 	 0.11 
100 
100
92HT599 B X4 2.1 	 0.11 7.7 	 0.23 
100 
100
93IN101 C R5 1.2 	 0.04 4.6 	 0.14 
100 
100
98IN017 C X4 1.6 	 0.1 3.6 	 0.06 
100 
100
92UG005 D R5 1.9 	 0.03 9.3 	 0.14 
100 
100
92UG024 D X4 0.8 	 0.05 7.8 	 0.06 
100 
100
92TH006 E R5 2.4 	 0.12 4.5 	 0.23 
100 
100
93TH053 E X4 2.3 	 0.11 7.4 	 0.19 
100 
100
93BR029 F R5 2.1 	 0.06 6.3 	 0.07 
100 
100
93BR020 F X4 1.0 	 0.02 4.9 	 0.25 
100 
100
RU132 G R5 0.4 	 0.06 3.3 	 0.03 
100 
100
Jv1083 G R5 2.4 / 0.13 7.2 	 0.17 
100 
100
Drug-resistant HIV-1 virusesa
RT74V 2.4 	 0.14 9.1 	 0.24 
100 
100
RTM184V 0.8 	 0.03 5.4 	 0.07 
100 
100
PRM46I/L63P/V82T/I84V 0.5 	 0.01 3.9 	 0.08 
100 
100
PRG48V/L90M 1.1 	 0.03 7.4 	 0.13 
100 
100
T20V38A/N42D 0.6 	 0.07 5.6 	 0.04 
100 
100
T20N425 1.4 	 0.1 8.3 	 0.5 
100 
100
Other retroviruses
SIVmac251 43H 1.7 	 0.04 6.9 	 0.3 
100 
100
SIVsyk1.2 1.3 	 0.02 5.4 	 0.16 
100 
100
HIV-2CDC310342 2.3 	 0.11 8.6 	 0.26 
100 
100
HIV-27312A 2.9 	 0.04 9.2 	 0.05 
100 
100
a Representative of various HIV-1 subtypes with different coreceptor usage.
b See Materials and Methods for a description of the viruses.
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FIG. 2. The syndecan-Fc hybrid molecule blocks HIV-1 infection of primary in vivo cell targets. (A) Blood-derived CD4 T lymphocytes,
macrophages, or DC (0.5  106 cells) were exposed to JR-CSF (1 ng of p24) and syndecan-1-Fc or control Fc (5 g/ml) for 1 day at 37°C and
washed. The amount of virus released was monitored by measuring amounts of capsid protein in cell supernatants by p24 ELISA. The points are
median values, and error bars represent standard errors of triplicates. The P values were calculated using a one-sided t test assuming equal
variances. d, day. (B) Cells were serially diluted from 55,000 cells to 25 cells in 100 l of complete medium. Fifteen microliters of the
CellQuanti-MTTTM reagent was added, and cells were incubated for 4 h at 37°C. Then, 100 l of the solubilization solution was added, and the
plate was shaken for 1 h at room temperature. The A570 was measured on a SpectraMax 384 Plus reader. To determine the cytotoxicity of Fc
proteins, cells (55,000) were treated twice daily with 200 g/ml of syndecan-1-Fc, Fc, or 0.01% saponin for a week. No washes were performed to
maintain a continuous exposure of cells to Fc proteins. OD, optical density.
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we asked whether syndecan-1-Fc inhibits HIV-1 infection
when added to cells for various lengths of time before or after
the addition of virus. Initially, we added syndecan-1-Fc or Fc to
TZM-bl cells at 1, 2, or 4 h before adding HIV-1 (R5 JR-CSF)
(1 ng of p24) or together with the virus (time zero), and it was
maintained in the culture until infection was monitored 48 h
later. Syndecan-1-Fc significantly inhibited infection when it
was added together with the virus (time zero) and up to 2 h
before the addition of the virus (Fig. 5A), indicating that the
syndecan-Fc hybrid molecule is highly potent in vitro at 37°C
for 4 h. Next, we asked whether syndecan-1-Fc can inhibit
HIV-1 infection when it was added after the virus is added to
target cells. Syndecan-1-Fc does not significantly block HIV-1
infection when it is added to cells after virus inoculation (Fig.
5A, posttreatment 1, 2, or 4 h) (). These data suggest that the
syndecan-Fc hybrid molecule is potent when added before
virus exposure.
Antiviral effect of the syndecan-Fc hybrid molecule on HIV-1
cell-to-cell transmission. Since HIV-1 can be transmitted ei-
ther as a cell-free or as cell-associated virus, we examined the
effect of syndecan-1-Fc on cell-to-cell transmission. To address
this issue, we added HIV-1-infected PBMCs to target TZM-bl
reporter cells in the presence of semen and increasing concen-
trations of syndecan-1-Fc. Importantly, we found that synde-
can-1-Fc significantly inhibits the infection of TZM-bl cells by
infected PBMCs (Fig. 5B). It is likely that syndecan-1-Fc, by
binding to the V3 region of gp120 on the surface of infected
PBMCs, interferes with cell-to-cell fusion. We found that
higher concentrations (100 g/ml) of syndecan-1-Fc were nec-
essary to inhibit cell-to-cell infection than cell-free infection
(Fig. 5B). This is likely due to the fact that cell-to-cell HIV-1
infection is more efficacious than cell-free infection (36).
The syndecan-Fc hybrid molecule blocks HIV-1 transmis-
sion in vitro. HIV-1 is thought to be sexually transmitted by
genital epithelium transmigration followed by DC- and/or LC-
mediated capture and transmission to CD4 T cells. We first
examined the antiviral effect of syndecan-1-Fc on HIV-1 epi-
thelial transmigration. To address this issue, we developed an
in vitro transwell chamber assay that mimics HIV-1 transcytosis
through PGEC (4). HIV-1 was added to the apical surface of
PGEC in the upper chamber of a transwell system for 8 h at
37°C, and the amount of transcytosed virus was quantified by
p24 ELISA in the lower chamber medium in contact with the
basal PGEC surface. Syndecan-1-Fc or control Fc was added to
the apical surface of the PGEC monolayer 30 min before the
virus was added. We chose to add Fc-syndecan to the transwell
30 min before the addition of the virus to simplify the design of
FIG. 3. The syndecan-Fc hybrid molecule blocks HIV-1 infection by inhibiting viral entry. CD4 T lymphocytes (500,000 cells) or macrophages
(150,000 cells) were exposed to 5 ng of p24 of JR-CSF in the presence or absence of syndecan-1-Fc or control Fc (5 g/ml). To measure virus
adsorption (A), cells were exposed to virus for 2 h at 4°C, washed twice with PBS, and lysed (not trypsinized), and amounts of capsid in cell lysate
were quantified by p24 ELISA. To measure virus internalization (B), plates containing cells and viruses were first centrifuged at 2,000  g
(spinoculation) for 3 h at 4°C. Cells were washed twice to remove unbound virus and then placed at 37°C for 4 h in the presence of Fc or
syndecan-1-Fc (5 g/ml). Cells were then trypsinized and lysed. Amounts of internalized virus were quantified by measuring amounts of capsid in
cell lysates by p24 ELISA. Results are expressed as the percentage of internalization relative to maximal adsorption, and internalization in the
absence of Fc proteins is arbitrarily fixed at 100. The points are median values (triplicate) and error bars represent standard errors of triplicates.
The P values were calculated using a one-sided t test assuming equal variances.
TABLE 2. Syndecan-Fc hybrid inhibition of HIV-1 JR-CSF
infection of CD4 T lymphocytes, macrophages, and DC
Target cell type
and donor
Syndecan-1-Fc activity
(g/ml)
Fc control
activity (g/ml)
IC50 IC90 IC50 IC90
CD4 T lymphocytes
Donor 1 1.1 	 0.03 3.2 	 0.14 
100 
100
Donor 2 0.8 	 0.04 2.5 	 0.13 
100 
100
Macrophages
Donor 1 1.5 	 0.02 4.6 	 0.21 
100 
100
Donor 2 0.9 	 0.03 3.1 	 0.13 
100 
100
DC
Donor 1 1.6 	 0.1 4.2 	 0.18 
100 
100
Donor 2 1.2 	 0.04 3 	 0.15 
100 
100
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the experiment since we found that adding the fusion protein
1 h before adding the virus to cells or at the same time similarly
inhibited HIV-1 infection (Fig. 5). In the absence of Fc pro-
teins, HIV-1 efficiently transmigrated through PGEC, in con-
trast to a virus lacking gp160 (Fig. 6A), suggesting that the viral
glycoprotein is absolutely required for transcytosis and that the
PGEC layer does not allow nonspecific transmigration of vi-
ruses. Amounts of transcytosed viruses were quantified by
measuring amounts of particulate capsid in the basal chamber.
Remarkably, syndecan-1-Fc, but not Fc, prevents HIV-1 trans-
migration through PGEC (Fig. 6A). We obtained similar re-
sults when we applied syndecan-1-Fc together with virus addi-
tion (data not shown). Importantly, syndecan-1-Fc exhibited
no cytotoxic effect on PGEC (Fig. 6C).
We then examined the capacity of the syndecan-Fc hybrid
molecule to prevent DC-mediated transmission of HIV-1. We
took advantage of a replication-defective virus (NL4.3Env-
eGFP), which does not encode Env but which has been
pseudotyped with HIV-1 Env (6). Pseudotyped viruses can
infect cells because they contain Env. However, cells that have
been infected by pseudotyped viruses cannot produce infec-
tious viruses because de novo viruses do not encode Env. Thus,
the use of pseudotyped viruses allowed the analysis of the
effect of the syndecan-Fc hybrid molecule on the transmission
of infectious particles from DC to T cells independently of DC
infection. DC were incubated with wild-type NL4.3-eGFP and
NL4.3-BaL-eGFP or pseudotyped NL4.3Env-eGFP/gp160
Env viruses. Two hours later, at which time the entry of the
virus into DC is completed (18), syndecan-1-Fc or control Fc
was added. After 2 h, DC were washed to remove both free
virus and Fc proteins. To measure DC–T-cell transmission,
Jurkat T cells were added for 3 days, and the percentage of
infected T cells (gated with an anti-CD3 antibody) was ana-
lyzed by FACS. Only pseudotyped viruses that have been rap-
idly transferred from DC to T cells through the virological
synapse (independently of DC infection) can infect T cells.
Indeed, pseudotyped viruses that infect DC can no longer
infect T cells because they do not encode Env. Because DC
were washed before T cells were added, the T-cell infection by
the pseudotyped virus observed in Fig. 6B could arise only
from pseudotyped particles that were transferred from DC to
T cells. Importantly, syndecan-1-Fc added to DC prevents sub-
sequent T-cell infection with the pseudotyped virus (Fig. 6B).
We obtained similar results when syndecan-1-Fc was added to
DC 1 h before virus was added (data not shown). This finding
suggests that syndecan-1-Fc neutralizes HIV-1 either before
FIG. 4. HS chain removal abrogates the anti-HIV activity of the syndecan-Fc hybrid molecule. (A) Blood-derived CD4 T lymphocytes (0.5 
106 cells) were exposed to JR-CSF (1 ng of p24) and untreated syndecan-1-Fc, heparinase-treated syndecan-1-Fc, or control Fc (5 g/ml) for 1 day
at 37°C and washed. The amount of virus released was monitored by measuring amounts of p24 capsid protein in cell supernatants by ELISA.
(B) The same experiment as in panel A was performed except that the 3HS-syndecan-1-Fc, which is devoid of its HS chains after mutagenesis
of its three glycosaminoglycan attachment sites, was tested for anti-HIV-1 activity. The points are median values, and error bars represent standard
errors of triplicates. The P values were calculated using a one-sided t test assuming equal variances.
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DC infection or during DC transfer to T cells. Thus, syndecan-
1-Fc interferes with HIV-1 transmission at multiple levels:
genital epithelial transmigration, DC infection or transfer to T
cells, and T cell infection.
Antiviral activities of the syndecan-Fc hybrid molecule are
preserved after low pH and genital fluid exposure. An ideal
microbicide should maintain its potency in the genital environ-
ment. We thus examined the inhibitory effect of the syndecan-Fc
hybrid molecule under conditions that mimic the genital envi-
ronment, such as exposure to low pH and genital fluids. We
first examined the antiviral effect of the syndecan-Fc hybrid
molecule at various pHs. Syndecan-1-Fc and Fc were incu-
bated at pH 2 to 9 and tested for their antiviral activities. As
expected, syndecan-1-Fc treated at a neutral pH (pH 7) neu-
tralizes HIV-1. Importantly, syndecan-1-Fc maintained its po-
tency in a basic (pH 8) or acidic (pH 4) environment (Fig. 7A),
suggesting that antiviral activities of the syndecan-Fc hybrid
molecule are preserved at low pH. We then examined the
antiviral effect of the syndecan-Fc hybrid molecule in seminal
plasma, cervical fluid, and vaginal mucus. Seminal plasma was
separated from sperm by centrifugation at 500  g for 10 min.
The pH was determined before and after the seminal plasma
was mixed with syndecan-1-Fc or Fc diluted in PBS. We found
that the original pH of seminal plasma is approximately 8.0 to
8.05 (n  8). Efficacy of syndecan-1-Fc against HIV-1 in the
presence of seminal plasma was conducted as follows. Fifty
microliters of serially 2-fold diluted syndecan-1-Fc in DMEM
was mixed with 50 l of JR-CSF and 50 l of either seminal
plasma or DMEM. The mixtures were added to TZM-bl indi-
cator cells, and infection was scored. Similar studies were con-
ducted with cervical fluid and vaginal mucus. Importantly, syn-
decan-1-Fc maintains its potent antiviral effect when diluted in
each of these genital fluids (Fig. 7B). Together, these features
are important with regard to the future use of the syndecan-Fc
hybrid molecule as a microbicide.
The syndecan-Fc hybrid molecule blocks HSV infection.
Since genital herpes increases transmission of HIV-1 (17), an
ideal microbicide should inhibit HIV-1 as well as HSV infec-
tion. We thus investigated whether the syndecan-Fc hybrid
molecule could also block HSV infection. To address this issue,
Vero cells were exposed to HSV-1-GFP or HSV-2-GFP (mul-
tiplicity of infection [MOI] of 0.1) in the presence of syndecan-
1-Fc or Fc. After 2 days, HSV infection was scored by FACS by
measuring the percentage of GFP-positive (GFP) Vero cells.
Importantly, we found that syndecan-1-Fc, but not Fc, inhibits
HSV-1 and HSV-2 infection (Fig. 8A). It is likely that synde-
can-1-Fc blocks HSV infection by interfering with the interac-
tion between HSV glycoproteins and entry receptors on Vero
cells. Since HSV exploits HS proteoglycans to enhance its
infection (7), it is likely that syndecan-1-Fc blocks HSV infec-
tion by interfering with the attachment of HSV to cell surface
HS expressed on Vero cells (i.e., syndecans). Supporting this
hypothesis, HS removal by enzymatic (heparinase treatment)
or genetic (3HS-syndecan-1-Fc) manipulation abrogates the
anti-HSV effect of the syndecan-Fc hybrid molecule (Fig. 8A).
As above (Fig. 2B, 5B and 6B), syndecan-1-Fc exhibited no
cytotoxic effect on Vero cells (Fig. 8B). Dual neutralization of
HIV-1 and HSV infection represents an additional micro-
bicidal property for the syndecan-Fc hybrid molecule.
DISCUSSION
In this study, we report that a syndecan-Fc hybrid molecule
has potent antiviral activity against HIV-1. Interestingly, many
antiviral properties of syndecan-1-Fc satisfy important precon-
ditions for the use of syndecan-1-Fc as a potential microbicide.
Syndecan-1-Fc (i) blocks HIV-1 infection of primary targets
including T cells, macrophages and DC; (ii) exhibits a broad
range of antiviral activity against primary HIV-1 isolates, mul-
tidrug resistant HIV-1 isolates, HIV-2, and SIV; (iii) prevents
FIG. 5. Antiviral effect of the syndecan-Fc hybrid molecule before, during, or after virus exposure. (A) Syndecan-1-Fc or control Fc (5 g/ml)
was added to TZM-bl cells 1, 2, or 4 h before (negative values on the y axis) or after (positive values on the y axis) the addition of HIV-1 (R5
JR-CSF) (1 ng of p24) or together (time zero) with the virus. Infection was measured 48 h after infection as -galactosidase activity. (B) Activated
PBMCs (200,000 cells) were infected with JR-CSF (500 pg of p24) for 3 days, washed three times to remove cell-free virus, and added to TZM-bl
cells in the presence of increasing concentrations of syndecan-1-Fc or control Fc (0.1 to 100 g/ml) diluted in a pool (n  6) of seminal plasma.
Infection was scored as above. The points are median values, and error bars represent standard errors of triplicates. The P values were calculated
using a one-sided t test assuming equal variances.
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transmigration of HIV-1 through primary human genital epi-
thelial cells; (iv) prevents HIV-1 transfer from DC to T cells;
(v) is potent when added 2 h prior to addition of HIV-1 to
cells; (vi) is potent at a low pH; (vii) efficiently blocks HIV-1
infectivity when diluted in genital fluids; and (viii) blocks HSV
infection. Thus, this syndecan-Fc hybrid molecule represents
the prototype of a new generation of microbicidal agents that
may have promise for HIV-1 prevention.
We previously showed that HIV-1 binds to cell surface syn-
decans via a highly conserved residue (Arg298) within the V3
region of gp120 (11). Interestingly, the same residue is critical
for gp120 binding to the CCR5 chemokine receptor (42). It is
thus likely that the syndecan-Fc hybrid molecule blocks HIV-1
infection by interacting with Arg298 and, therefore, by inter-
fering with both viral adsorption and coreceptor-mediated en-
try. Since compounds that interrupt gp120-syndecan interac-
tions have never been exploited as microbicides, they represent
a novel class of microbicides and thus differ from existing tools.
One advantage of using compounds that target gp120-synde-
can interactions as microbicides is that all primary R5, X4, and
R5X4 HIV-1 as well as HIV-2 isolates bind syndecans. Thus,
these compounds will have a broader impact than, for example,
RANTES derivatives, which neutralize R5 viruses only (24).
Since we found that compounds that block gp120-syndecan
interactions also block gp120-CCR5 interactions (11), their
dual inhibitory effects represent another advantage of using
them as microbicides. Supporting this notion, we found that
the syndecan-Fc hybrid molecule blocks a broad spectrum of
FIG. 6. The syndecan-Fc hybrid molecule inhibits both HIV-1 transmigration and HIV-1 transfer from DC to T cells. (A) Pseudotyped
NL4.3Env/gp160 R5 Env virus (25 ng of p24) or Gp160-deficient NL4.3Env virus (25 ng of p24) was added to the apical surface of PGEC.
Syndecan-1-Fc or control Fc (5 g/ml) was added to PGEC 30 min before the virus was added. Amounts of transcytosed viruses in the basal
chamber were quantified by p24 ELISA. Results are expressed as a percentage of p24 of the original inoculum. The points are median values, and
error bars represent standard errors of triplicates. (B) DC (100,000 cells) were incubated for 2 h at 37°C with wild-type NL4.3-eGFP (X4 virus)
and NL4.3-BaL-eGFP (R5 virus) viruses or with the pseudotyped NL4.3Env-eGFP/gp160 X4 Env virus (25 ng of p24). Syndecan-1-Fc or control
Fc (5 g/ml) was added 2 h later. DC were washed 2 h after the Fc proteins were added, Jurkat T cells (100,000 cells) were added for 3 days, and
the percentage of infected Jurkat T cells was analyzed. The percentage of HIV-infected Jurkat T cells (gated by using an anti-CD3 antibody) in
DC-T-cell coculture was analyzed by GFP expression on day 5. Error bars represent standard errors of duplicates. (C) The experiment is as
described in the legend of Fig. 2B.
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X4, R5, and R5X4 viruses. Although it is likely that in vivo
syndecan-1-Fc-resistant HIV-1 variants should arise, we were
unsuccessful at developing such resistant variants in vitro. Nev-
ertheless, it is important to emphasize that the “perfect” mi-
crobicide will likely be composed of several anti-HIV-1 agents
that target viral proteins other than gp120 (i.e., RT) and there-
fore should neutralize emerging syndecan-1-Fc-resistant
HIV-1 variants. Another advantage of using a syndecan-Fc
hybrid molecule as a microbicide is that many sexually trans-
mitted pathogens also exploit syndecans for host colonization,
such as HSV (7), HPV (13, 37), and Neisseria gonorrhoeae (15,
41). Supporting this hypothesis, we found that the syndecan-Fc
hybrid molecule efficiently blocks HSV infection (Fig. 8).
One cannot exclude the possibility that syndecan-1-Fc has
adverse effects in the vaginal environment after its topical
administration. One can envision that the hybrid molecule, by
capturing specific cytokines or chemokines via its HS chains,
enhances the suppression of immune activation and increases
the inflammation state mediated by HIV-1 (9). Similarly, syn-
decan-1-Fc may play a detrimental role during HIV-1 trans-
mission by capturing and neutralizing cationic antimicrobial
polypeptides (i.e., defensins), which are the principal effector
molecules of mucosal innate immunity against microbes and
viruses such as HIV-1 (8). However, we do not anticipate that
syndecan-Fc (60 to 90 kDa), which is extremely soluble and
does not make aggregates even at high concentrations, would
cause discomfort to humans or animals. Indeed, the ectodo-
main of syndecans, which we fused to an IgG1 Fc portion, is
constitutively and constantly shed by human cells without af-
fecting cell viability (1). The extracellular domain of synde-
can-1 is proteolytically cleaved at a juxtamembrane site by a
tissue inhibitor of metalloprotease-3-sensitive metalloprotein-
FIG. 7. The syndecan-Fc hybrid molecule is still active after low pH and genital fluid exposure. (A) TZM-bl cells (20,000 cells) were exposed
to JR-CSF (100 pg of p24). Syndecan-1-Fc or control Fc was treated for 8 h at various pHs and added to cells (final concentration of 5 g/ml)
together with virus. Infection was measured 48 h postinfection by -galactosidase activity. (B) Syndecan-1-Fc or control Fc was diluted in medium,
a pool (n  6) of seminal plasma, a pool of cervical fluid (n  8), and a pool (n  4) of vaginal mucus. The dilutions were then added to TZM-bl
cells together with HIV-1 (100 pg of p24). Infection was measured 48 h postinfection by -galactosidase activity. Results are expressed as relative
light units. The points are median values, and error bars represent standard errors of triplicates. The P values were calculated using a one-sided
t test assuming equal variances.
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ases in response to a variety of physiological stimulators in a
process known as shedding (43). Shedding converts syndecan-1
from a membrane-bound coreceptor into a soluble effector
capable of binding the same ligands. Thus, the nature of syn-
decan-1-Fc (ectodomain of existing human receptors fused to
human antibody fragments) significantly diminishes the risk of
adverse effects.
Another disadvantage of using syndecan-1-Fc as a topical
microbicide is that its antiviral effect wanes in 4 h (Fig. 5).
Interestingly, we found by FACS analysis that syndecan-Fc
binds efficiently to HeLa cells (data not shown). It is likely that
syndecan-Fc binds to HeLa cells by binding either to Fc recep-
tors expressed on HeLa cells or to cytokines, chemokines, or
growth factors bound onto the surface of HeLa cells. An ad-
equate formulation of syndecan-1-Fc allowing a slow release of
the fusion protein should, hopefully, partially alleviate this
obstacle. Since syndecan-1-Fc loses its antiviral effect when
added to cells 1 h after virus exposure, it would therefore need
to be applied shortly before coitus and would not have long-
lasting effects like other potential microbicides.
A series of microbicides has been developed (i.e., sulfated
and sulfonated polymers) that most likely work similarly to
syndecan-1-Fc. Importantly, a majority of these microbicidal
candidates (carrageenan [the active ingredient in Carraguard],
cellulose sulfate, PRO-2000, and dextran sulfate) failed to pro-
vide protection in humans (27, 40). It has been proposed that
this failure arises from a limited in vitro potency of these
sulfated compounds against R5 viruses, the most commonly
transmitted strains of HIV-1 (27, 40). Moreover, evidence
emerged that cellulose sulfate enhances HIV-1 infection in
vitro, particularly of R5 viruses (27, 40). Thus, although synde-
can-1-Fc efficiently blocks both X4 and R5 viruses and does not
promote HIV-1 infection, it is still possible that the topical
administration of syndecan-1-Fc in vivo would not provide any
protection. Importantly, syndecan-1-Fc is currently being
tested in a vaginal HIV-1 transmission model in macaque.
Indeed, we believe that any microbicide candidate should dem-
onstrate proof of both safety and efficacy in a macaque model
before being considered for human trials. Evidently, success in
a macaque model would not guarantee that syndecan-1-Fc will
protect women, but a failure to protect monkeys would be
considered a serious sign that it lacks potency.
Another concern with regard to the future development of
syndecan-1-Fc as a microbicide is that it exhibits a potent
FIG. 8. The syndecan-Fc hybrid molecule blocks HSV infection. Vero cells (250,000 cells) were exposed to HSV-1-GFP or HSV-2-GFP (MOI
of 0.1) together with control Fc, syndecan-1-Fc, heparinase-treated syndecan-1-Fc, or 3HS syndecan-1-Fc lacking HS chains (5 g/ml). After 2
days, Vero cell infection was scored by FACS by quantifying the percentage of GFP cells. Data are expressed in percentage of GFP cells. The
points are median values, and error bars represent standard errors of triplicates. The P values were calculated using a one-sided t test assuming
equal variances. (B) The experiment is as described in the legend of Fig. 2B.
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antiviral activity only when used at a g/ml range (Tables 1 and
2). To avoid having to use too high a concentration of synde-
can-1-Fc in vivo, we propose to optimize the potency of the Fc
hybrid molecule. We previously reported that the degree of
sulfation of heparan sulfates directly correlates with their po-
tential to neutralize HIV-1 (3). Specifically, we showed that the
removal of the 6-O sulfation dramatically decreases the anti-
HIV-1 effect of heparan sulfate analogs, whereas oversulfation
significantly increases their inhibitory effect (3). Thus, with
regard to future optimization of syndecan-1-Fc, we will exam-
ine whether manipulating the degree of sulfation of syndecan-
1-Fc would improve its potency and therefore would diminish
the amounts of syndecan-1-Fc needed for protection.
Protein microbicides such as syndecan-1-Fc could represent
promising alternatives to the current generation of small-mol-
ecule drugs. However, producing and distributing such pro-
teins in key areas of HIV endemicity are difficult and expensive
because of the lack of a fermentor and a cold chain. Interest-
ingly, many therapeutic proteins have been expressed in plants,
including a large number of vaccine candidates and various
recombinant antibody formats (32). The most important ben-
efits of using plants such as maize seeds over fermentor-based
systems include the enhanced stability of recombinant proteins
accumulating in the endosperm, which means that a cold chain
is not necessary for product distribution (32), as well as the
economy of large-scale production, which will make the prod-
uct more affordable. In other words, if syndecan-1-Fc provides
protection in a vaginal SHIV transmission model in macaques,
the production of syndecan-1-Fc in plants should be consid-
ered.
In conclusion, this study demonstrates that syndecan-1-Fc
possesses numerous microbicidal in vitro properties against
HIV-1. Specifically, syndecan-1-Fc can block HIV-1 transmis-
sion at multiple levels: trans-epithelial migration, DC-medi-
ated transfer to T cells, and cis infection of CD4 T lympho-
cytes, macrophages, and DC. Future safety and efficacy in vivo
studies using humanized mice and macaque vaginal simian-
human immunodeficiency virus (SHIV) transmission models
will determine whether syndecan-Fc hybrid molecules truly
represent prototypes of a new generation of microbicidal
agents against HIV-1.
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